Authors:
JM Reese, ES Bruinsma, AW Nelson, I Chernukhin, JS Carroll, Y Li, M Subramaniam, VJ Suman, V Negron, DG Monroe, JN Ingle, MP Goetz, JR Hawse
Journal name: 
Proc Natl Acad Sci U S A
Citation info: 
115(41):E9580-E9589
Abstract: 
Triple-negative breast cancer (TNBC) accounts for a disproportionately high number of deaths due to a lack of targeted therapies and an increased likelihood of distant recurrence. Estrogen receptor beta (ERβ), a well-characterized tumor suppressor, is expressed in 30% of TNBCs, and its expression is associated with improved patient outcomes. We demonstrate that therapeutic activation of ERβ elicits potent anticancer effects in TNBC through the induction of a family of secreted proteins known as the cystatins, which function to inhibit canonical TGFβ signaling and suppress metastatic phenotypes both in vitro and in vivo. These data reveal the involvement of cystatins in suppressing breast cancer progression and highlight the value of ERβ-targeted therapies for the treatment of TNBC patients.
DOI: 
http://doi.org/10.1073/pnas.1807751115
Research group: 
Carroll Group
E-pub date: 
30 Sep 2018
Users with this publication listed: 
Jason Carroll